Nuformix (LON:NFX) Stock Price Down 11.1% – Time to Sell?

Nuformix plc (LON:NFX) traded down 11.1% on Thursday . The stock traded as low as GBX 0.24 and last traded at GBX 0.24. 8,196,036 shares changed hands during trading, a decline of 77% from the average session volume of 36,088,453 shares. The stock had previously closed at GBX 0.27.

Nuformix Stock Down 7.4%

The firm has a market cap of £5.27 million, a P/E ratio of -6.36 and a beta of 1.22. The business has a fifty day simple moving average of GBX 0.26 and a 200-day simple moving average of GBX 0.23.

Nuformix (LON:NFX) last issued its quarterly earnings results on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.